What changed
Anavex Life Sciences received confirmation from Nasdaq that it has regained compliance with Listing Rule 5250(c)(1). The Company filed its outstanding Form 10-Q reports for the second and third fiscal quarters of 2026 on August 28, 2026. Its common stock will continue to trade on the Nasdaq Global Select Market under ticker AVXL.
Why it matters
Anavex Life Sciences received confirmation from Nasdaq that it has regained compliance with Listing Rule 5250(c)(1). The Company filed its outstanding Form 10-Q reports for the second and third fiscal quarters of 2026 on August 28, 2026. Its common stock will continue to trade on the Nasdaq Global Select Market under ticker AVXL.
← Dashboard
Sep 04, 2026 06:52 PM ET